Tuberculosis treatment. A practical guide elaborated by the Tuberculosis Section, Argentine Association of Respiratory Medicine;Tratamiento de la tuberculosis. Guia practica elaborada por la Seccion Tuberculosis, Asociacion Argentina de Medicina Respiratoria

Medicina

Volumn 67, Issue 3, 2007, Pages 295-305

  Abbate, Eduardo H ^a,e   Palmero, Domingo J ^a   Castagnino, Jorge ^a   Cufre, Monica ^a   Doval, Alejandra ^b   Estevan, Rosa ^a   Kuriger, Adriana ^a   Limongi, Leticia ^c   Moraña, Eduardo ^a   Musella, Rosa ^a   Pibida, Carlos ^a   Putruele, Ana Maria ^c   Tanco, Susana ^d   Vescovo, Marisa ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

^b Programa de Tuberculosis de la Provincia de Entre Ríos   (Argentina)

^c HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^d Hospital Maria Ferrer   (Argentina)

^e Instituto María Ferrer ^*  (Argentina)

Author keywords

Practical guidelines; Treatment; Tuberculosis

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; ANASTROZOLE; ATORVASTATIN; BEPRIDIL; BUSULFAN; CARBAMAZEPINE; CIMETIDINE; CLONAZEPAM; CYCLOSERINE; DIAZEPAM; DILTIAZEM; ENALAPRIL; ETHAMBUTOL; ETOPOSIDE; HYDROCORTISONE; ISONIAZID; KETOCONAZOLE; LIDOCAINE; LOSARTAN; MOXIFLOXACIN; OFLOXACIN; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNINDEXED DRUG;

ACNE; ACUTE KIDNEY FAILURE; ALOPECIA; ANEMIA; ARGENTINA; ARTHRITIS; ARTICLE; CONSENSUS DEVELOPMENT; CONTACT DERMATITIS; CONVULSION; DELIRIUM; DEPRESSION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL TOXICITY; GRAVES DISEASE; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; IMMUNOTOXICITY; LUNG LOBECTOMY; LUNG TUBERCULOSIS; LUPUS ERYTHEMATOSUS; MEDICAL SOCIETY; MEDICAL SPECIALIST; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PSYCHOSIS; QT PROLONGATION; RETREATMENT; RETROBULBAR OPTIC NEUROPATHY; TENDINITIS; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT INDICATION;

ANTITUBERCULAR AGENTS; ARGENTINA; HUMANS; RETREATMENT; TUBERCULOSIS, PULMONARY;

EID: 34447296165     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. World Health Organization (WHO) report 2006. Global tuberculosis control - surveillance, planning, financing. WHO/HTM/TB/2006.362
2. Instituto Nacional de Enfermedades Respiratorias (INER) Emilio Coni, Santa Fe. Situación de la tuberculosis. República Argentina 2004. PRO.TB.DOC.TEC 04/05. inerconiιnfovia.com.ar
3. WHO. Treatment of tuberculosis. Guidelines for national programmes. WHO/ CDS/TB/2003.313.
4. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB 2006.361
5. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: Treatment of tuberculosis. Am J Resp Crit Care Med 2003; 167: 603-62.
6. Programa Nacional cle Control de la Tuberculosis. Normas técnicas 2002. INER Coni: inerconiιnfovia.com.ar
7. Goodman and Gilman's. The pharmacological basis of therapeutics. 10th Ed. New York: Mc Graw Hill, 2001, p 1242-371.
8. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77: 1253-62.
9. Palmero D J, Waisman JL. Tratamiento de la tuberculosis multirresistente. En: González Montaner LJ, Palmero DJ y col. Tuberculosis Multirresistente. Buenos Aires, Ed. Hoechst Marion Roussel, 1998, p 131-47.
10. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central: nervous system infections. Clinical Pharmacokinetics 1998; 35: 223-46.
11. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 2971-3.
12. Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev 2004; 36: 497-509.
13. Caminero Luna JA. Guía de la tuberculosis para médicos especialistas. Paris, Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias (UICTER), 2003, p 156-92.
14. WHO. Anti-tuberculosis drug resistance in the world. Report no 3. WHO/ HTM/TB/2004.343
15. Grosset J. Bacteriological basis for short-course chemotherapy for tuberculosis. Clin Chest Med 1980; 1: 231-242.
16. Moulding T. Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122: 951-54.
17. Thwaites GE, Duc Bang N, Dung NH, et al. Dexamethasone for the treatment of tuberculosis meningitis in adolescents and adults. N Eng J Med 2004; 351: 1741-51.
18. Crofton J. Tuberculosis: Propter Koch, Post Koch: a global review. The Robert Koch memorial lecture of the International Union Against Tuberculosis and Lung Disease, Mainz, June 1994. IUATLD Newsletter 1994; 2.
19. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Eng J Med 2003; 348: 119-28.
20. Caminero Luna JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Resp J 2005; 25: 928-36
21. Corti M, Palmero D. Tratamiento antirretroviral en pacientes con sida y micobacteriosis. Medicina(Buenos Aites) 2005; 65: 353-60.
22. Bartlett JG. Terapéutica de las Enfermedades Infecciosas. Buenos Aires: Waverly Hispánica SA, 2000, p 36-52.
23. Abbate EH, Chertcoff J, Musella RM.: Anemia hemolitica provocada por rifampicina. Anales de la Cátedra de Tisioneumonología UBA 1980; 39: 5-7.
24. González Montaner LJ, Castagnino JP, Musella RM: The nature and frequency of serious adverse drugs reactions to antituberculous therapy among HIV infected patients. Am Rev Respir Dis 1991; 143 (S): A116.
25. The global alliance for TB drug development 2001. Scientific blueprint, p:1-52. http://www.tballiance.org/pdf/ TB%20Scientific%20Blueprint%20Full.pdf (Consultado el 24/9/05).
26. Iseman MD. Tuberculosis therapy: past, present and future. Eur Respir J 2002; 20: 87-95.
27. Kremer L, Besra GS. Current status and future development of antitubercular chemotherapy. Expert Opin Investig Drugs 2002; 11: 1033-49.
28. Park-Wyllie LY, Juurlink DN, Kopp A. Outpatient gatifloxacin therapy and disglycemia in older adults. N Engl J Med 2006; 354: 1352-61.
29. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopiran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
30. Andries K, Verhasselt P, Guillemon T, et al. A diarylquinolina drug active on the ATP synthasa of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
31. Abbate E, Brea A, Cufré M, et al. Linezolid in multidrug-resistant tuberculosis treatment. Eur Respir J 2004; 24 (S48):485.
32. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines in antibiotic-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 2001; 47: 505-11.
33. Barry III CE. Laboratory of immunogenetics. Tuberculosis research section. http://www.niaid.nih.gov/dir/labs/lhd/barry.htm. (consultado el 12/9/05).
34. Palmero D, Eiguchi K, Rendo P, Castro Zorrilla L, Abbate E, González Montaner LJ. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int J Tuberc Lung Dis 1999; 3: 214-8.
35. Abbate EH, Dambrosi A, Di Lonardo M, González Montáner LJ. Multiple drug-resistant pulmonary tuberculosis - Fourteen years experience in Buenos Aires, Argentina. Tuberc Lung Dis 1994; 75 (Suppl.): 34.
36. Chan ED, Laurel V, Strand M, Chan J, Huynh, Goble M, Iseman M. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-9.